The FDA has rejected a biologics license application for apitegromab to treat spinal muscular atrophy, according to manufacturer Scholar Rock.
IL date: March 26 (retroactive to March 24, transferred to 60-day IL on June 4) Expected return: 2026 Status: Was returned from his rehab assignment, retroactive to Sept. 19, and is expected to resume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback